Social media

What does it take to lead with both heart and science? In the second installment of our employee spotlight series #BehindBiotech, we meet Dr. Mark Sorrentino - Vice President and Head of ICON’s Centre for Pediatric Clin...

Biomarkers aren’t just supporting drug development, they’re driving it. This expert-led report produced in conjunction with Drug Target Review explores how biomarker science is advancing trial design, accelerating clinic...

Faster access to life-saving therapies is within reach. Global regulators are working together to speed approvals for oncology and rare disease treatments—but navigating these pathways takes foresight and expertise. Ou...

At #DPHARM2025 on 17 September at 3:40 PM, Faith Gabel will lead a pivotal session on evolving site networks beyond transactional execution toward delivering lasting value. Her insights will help clinical research profe...

A sponsor of an Alzheimer's study sought ICON’s support with patient recruitment when the study had an unexpectedly high screen failure rate. Our teams screened 1,600+ patients in ten countries and completed recruitment ...

Sponsors face growing expectations in obesity trials: • Generating richer, patient-centered outcomes • Submitting evidence that meets regulatory requirements • Ensuring operational feasibility in real-world settings Our...

Overwhelmed by the flood of life sciences research? Systematic literature reviews (SLRs) are your toolkit for clarity, credibility, and impact. Learn how to build a strong protocol - Avoid common pitfalls - Apply frame...

We are proud to share that ICON has been recognised by Marksmen Daily as one of India’s Most Preferred Workplaces 2025–26. This award celebrates organisations that foster an environment where people can thrive through c...

ICON has analysed ECG data from over 22,000 healthy volunteers to compare four widely used QT correction formulae. This large-scale study offers new insights into how age and BMI influence QT-interval adjustment – an are...

After a slow start, Project #Optimus is gaining traction among #biotechs. On the latest BioCentury Inc.: This Week podcast, ICON’s Dr Liz O’Brien, Senior Director, Drug Development Solutions, shares expert insights on ho...

The specific needs of oncology clinical trials, alongside the distinct clinical pathway for biosimilars, mean that developing these treatments must be approached very differently from novel biologic development. To under...

In recognition of National Immunisation Month, ICON experts analyse modern vaccine technologies. Learn about nucleic acid-based vaccine technologies, and vaccine delivery systems including viral vectors, virus-like par...